The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice

British Journal of Pharmacology

Volumn 156, Issue 7, 2009, Pages 1067-1075

  Van Der Hoorn, J W A ^a,b   Jukema, J W ^b   Havekes, L M ^a,b   Lundholm, E ^c   Camejo, G ^c   Rensen, P C N ^b   Princen, H M G ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

3Leiden.CETP mice; APOE; Atherogenic triad; Atherosclerosis; PPAR ; Tesaglitazar

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; COLLAGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; TESAGLITAZAR; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; 2 ETHOXY 3 (4 ((4 (METHYLSULFONYLOXY)PHENETHYL)OXY)PHENYL)PROPANOIC ACID; 2-ETHOXY-3-(4-((4-(METHYLSULFONYLOXY)PHENETHYL)OXY)PHENYL)PROPANOIC ACID; ALKANESULFONIC ACID; APOLIPOPROTEIN E3; APOLIPOPROTEIN E3 (LEIDEIN); PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLPROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTERY MUSCLE; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONTENT; SMOOTH MUSCLE FIBER; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; AORTA VALVE; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; DRUG POTENTIATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ALKANESULFONATES; ANIMALS; AORTIC VALVE; APOLIPOPROTEIN E3; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, TRANSGENIC; MUTATION; PHENYLPROPIONATES; PPAR ALPHA; PPAR GAMMA;

EID: 67650698528     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00109.x     Document Type: Article

References (49)

1. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M (2007a). PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 56 : 91 98.
2. Balakumar P, Rose M, Singh M (2007b). PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 80 : 1 10.
3. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES (2005). Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 : 185 197.
4. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S et al. (2007). PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6 : 137 143.
5. Bouhlel MA, Staels B, Chinetti-Gbaguidi G (2008). Peroxisome proliferator-activated receptors - from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. J Intern Med 263 : 28 42.
6. Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC (2007). Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195 : 17 22.
7. Chira EC, McMillen TS, Wang S, Haw A III., O'Brien KD, Wight TN et al. (2007). Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 195 : 100 109.
8. De Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM et al. (2008a). Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 197 : 57 63.
9. De Haan W, de Vries-Van der Weij J, van der Hoorn JW, Gautier T, van der Hoogt CC, Westerterp M et al. (2008b). Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 117 : 2515 2522.
10. Delsing DJ, Offerman EH, van Duyvenvoorde W, van der Boom H, de Wit EC, Gijbels MJ et al. (2001). Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 103 : 1778 1786.
11. Delsing DJ, Jukema JW, Van de Wiel MA, Emeis JJ, Van der Laarse A, Havekes LM et al. (2003). Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 42 : 63 70.
12. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM (2007). The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 : 1772 1780.
13. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al. (1987). Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 : 1237 1245.
14. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N et al. (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 : 1096 1105.
15. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP (2006). Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin 22 : 2575 2590.
16. Gordon DJ, Rifkind BM (1989). High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 321 : 1311 1316.
17. Grundy SM (1998). Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 81 : 18B 25B.
18. Guerin M, Dolphin PJ, Chapman MJ (1994a). A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler Thromb 14 : 199 206.
19. Guerin M, Dolphin PJ, Chapman MJ (1994b). Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb 14 : 679 685.
20. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A (1992). Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 90 : 1290 1295.
21. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 : 2427 2443.
22. Keating GM, Croom KF (2007). Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67 : 121 153.
23. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 : 1849 1861.
24. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ et al. (2003). Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 108 : 1368 1374.
25. Kooistra T, Verschuren L, de Vries-Van der Weij J, Koenig W, Toet K, Princen HM et al. (2006). Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 26 : 2322 2330.
26. Libby P, Plutzky J (2007). Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 99 : 27B 40B.
27. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 : 1180 1188.
28. Mann CJ, Yen FT, Grant AM, Bihain BE (1991). Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 88 : 2059 2066.
29. Marzetta CA, Meyers TJ, Albers JJ (1993). Lipid transfer protein-mediated distribution of HDL-derived cholesteryl esters among plasma apo B-containing lipoprotein subpopulations. Arterioscler Thromb 13 : 834 841.
30. Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A et al. (2006). Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 26 : 845 850.
31. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T et al. (2004). Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 : 2728 2735.
32. Nissen SE, Wolski K (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 : 2457 2471. (Pubitemid 46919772)
33. Rader DJ (2007). Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 120 : S12 S18.
34. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 : 410 418.
35. Schuster H, Fagerberg B, Siôn E, Halmos T, Lopatynski J, Stender S et al. (2008). Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 197 : 355 362.
36. Staels B, Fruchart JC (2005). Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 : 2460 2470. (Pubitemid 41134276)
37. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (1998). Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 : 2088 2093.
38. The BIP Study Group (2000). Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 : 21 27.
39. Tonstad S, Retterstol K, Ose L, Ohman KP, Lindberg MB, Svensson M (2007). The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. Metabolism 56 : 1285 1292.
40. Van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, de Bruijn I, van Vlijmen B, van der Boom H et al. (1993). Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 268 : 10540 10545.
41. Van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA et al. (2007). Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 48 : 1763 1771.
42. Van der Hoorn JW, Kleemann R, Havekes LM, Kooistra T, Princen HM, Jukema JW (2007). Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. J Hypertens 25 : 2454 2462.
43. Van der Hoorn JW, de Haan W, Berbée JFP, Havekes LM, Jukema JW, Rensen PCN et al. (2008). Niacin increases HDL by reducing hepatic expression and plasma levels and cholesteryl ester transfer protein in APOE*3Leiden. CETP mice. Arterioscler Thromb Vasc Biol 28 : 2016 2022.
44. Van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, van der Boom H, HogenEsch H, Frants RR et al. (1994). Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93 : 1403 1410.
45. Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HM et al. (2005). Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 25 : 161 167.
46. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW et al. (2006). Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26 : 2552 2559.
47. Wild S, Roglic G, Green A, Sicree R, King H (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 : 1047 1053.
48. Zadelaar AS, Boesten LS, Jukema JW, van Vlijmen BJ, Kooistra T, Emeis JJ et al. (2006). Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol 26 : 2560 2566.
49. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn JW, Princen HM et al. (2007). Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27 : 1706 1721.